| http://www.w3.org/ns/prov#value | - [06/11/2014] Introducing competing biosimilar versions of complex biologic drugs used to treat illnesses such as cancer and rheumatoid arthritis could cut spending on biologics in the United States by $44 billion over the next decade, according to new analysis from the RAND Corporation.Biosimilar drugs could create billions in health care savings - Read more
|
